Octane Medical Group News Releases

BioOra and Octane Biotech Sign Letter of Intent to Expand Cell Therapy Manufacturing Using the Cocoon(R) Platform

Tue, 07 Apr 2026 10:15:00 -0400

Collaboration builds on CAR-T commercialization in New Zealand and supports expansion across Australia, North America and other international markets. Wellington, New Zealand and Kingston, Ontario--(Newsfile Corp. - April 7, 2026) - BioOra Limited ("BioOra"), a commercial-stage cell therapy company advancing CAR-T therapies for cancer patients, and Octane Biotech Inc., an Octane Medical Group Company ("Octane"), today announced the signing of a Letter of Intent (LOI) to collaborate on the...

Octane Medical Group Signs Agreement to Acquire Lonza's Personalized Medicine Business

Wed, 04 Mar 2026 18:00:00 -0500

Kingston, Ontario--(Newsfile Corp. - March 4, 2026) - Octane Medical Group ("Octane") today announced that it has entered into a definitive agreement to acquire Lonza's Personalized Medicine business. For Octane, this is a strategically significant deal that comprises Lonza's controlling stake in the Cocoon® Platform - originally acquired from Octane in 2018 - alongside associated intellectual property (IP), workforce and existing customer contracts. Completion of the transaction is subject to...

Octane Medical Acquires B. Braun's Global Orthobiologics Business

Fri, 07 Jun 2024 11:11:00 -0400

"From the start, our corporate mission has been to make regenerative medicine the standard of care. We continue to be true to this goal, and it's the key reason why we pursued this opportunity." - Octane Medical Group CEO Timothy Smith.Kingston, Ontario, and Melsungen, Germany--(Newsfile Corp. - June 7, 2024) - Octane Medical Group, through its new venture Octane Biotherapeutics (BioTx), has acquired 100% shares of the global orthobiologics business from its long-term partner B. Braun. The...